Hanneke Schuitemaker is a Dutch virologist, the Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson's Janssen Vaccines & Prevention, and a Professor of Virology at the Amsterdam University Medical Centers of the University of Amsterdam (since 2004).

[1] As a child she was fascinated by medicine, and after earning her undergraduate degree she completed a PhD programme in AIDS pathogenesis at the University of Amsterdam.

[1] She started working at Sanquin, the Netherlands blood supply foundation based in Amsterdam, where she was made Head of the department of Clinical Viro-Immunology in 1998.

[2] Schuitemaker joined the Academic Medical Center in Amsterdam in 2008, where she was made Chair of Experimental Immunology.

[6] Schuitemaker demonstrated the efficacy of the adenovirus/protein vaccines against simian immunodeficiency virus in rhesus macaques.

[1][9] Results of Imbokodo, an investigation into the potential for this vaccine to save the lives of thousands of young women in Sub-Saharan Africa, are expected in 2021.

In mid-May, she announced that Janssen's most hopeful vaccine variant will be tested on humans in July 2020.